STOCKHOLM3 PSA PLUS
LIVE

Serial Number

79454284

Owner

A3P Biomedical AB (publ)

Filing Date

Apr 28, 2026

Add to watchlist:

No watchlists yet
View on USPTO

STOCKHOLM3 PSA PLUS Trademark

Serial Number: 79454284

STOCKHOLM3 PSA PLUS is a trademark filed by A3P Biomedical AB (publ) on April 28, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

A3P Biomedical AB (publ) (2 trademarks)

Kungsgatan 24

Entity Type: 98

Trademark Details

Filing Date

April 28, 2026

Registration Date

Not Registered

Goods & Services

IT integration services; computer software development, programming and implementation for others; website hosting services; software as a service (SaaS) featuring computer software for calculating prostate cancer risk scores; rental of computer software for use in calculating cancer risk; providing temporary use of online non-downloadable computer software for calculating prostate cancer risk scores; application service provider featuring computer software for calculating prostate cancer risk scores; scientific research and analysis in the field of prostate cancer; medical and pharmacological research services in the field of prostate cancer; conducting clinical trials for others in the field of prostate cancer; scientific and medical research in the field of oncology and urology; providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; providing information on clinical studies via an interactive website.

Downloadable software for calculating the risk of prostate cancer; downloadable computer programs for calculating the risk of prostate cancer; downloadable computer software for prostate cancer testing; downloadable application software for calculating the risk of prostate cancer; scientific research and laboratory apparatus for measuring, quantification and analysis of proteins and genetic material; medical training simulators for educational purposes in the field of prostate cancer; scientific research and laboratory instruments for detecting proteins and genetic material for medical research and training purposes; computer peripherals devices.

Medical instruments, namely, protein and genetic measuring instruments for medical diagnostic purposes; medical apparatus and instruments for the diagnosis, examination, monitoring and treatment of prostate cancer; medical testing apparatus and instruments for detecting and diagnosing prostate cancer; testing probes for medical diagnostic purposes; medical diagnostic tools for calculating prostate cancer risk.

Human healthcare services, namely, disease management programs; medical services in the field of oncology and urology; medical diagnostic services in the field of oncology and urology; medical diagnostic testing services for prostate cancer; prostate cancer screening services; medical analysis services for the diagnosis and treatment of cancer and related diseases; providing online information services relating to medical and diagnostic tests, namely information regarding prostate cancer tests for diagnosis and treatment purposes; phlebotomy services; medical blood testing services; blood sampling and analysis for diagnostic or treatment purposes; providing medical information relating to prostate cancer test results; providing medical information relating to medical diagnostic test results; medical analysis services for diagnostic provided by medical laboratories; medical laboratory analysis services for the analysis of samples and blood samples taken from patients for diagnostic purposes; rental of medical equipment for use in human healthcare; medical consultancy services in the field of oncology and urology; providing medical information in the field of oncology and urology.

Diagnostic test reagents for medical purposes for prostate cancer testing; pharmaceutical preparations for treatment of cancer; reagents for use in diagnostic tests for medical purposes; diagnostic test materials for medical purposes; diagnostic preparations for medical purposes; diagnostic agents for medical use.

Filing History

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 30, 2026 RFCR
NON-FINAL ACTION WRITTEN
Jul 29, 2026 CNRT
ASSIGNED TO EXAMINER
Jul 22, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 17, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 17, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 16, 2026 REPR